Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients
about
Economic Evaluation of Pharmacogenetic Tests in Patients Subjected to Renal Transplantation: A Review of LiteratureTacrolimus in preventing transplant rejection in Chinese patients--optimizing useEvaluation of molecular profiles in calcineurin inhibitor toxicity post-kidney transplant: input to chronic allograft dysfunction.The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.PharmGKB summary: cyclosporine and tacrolimus pathwaysErlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.Role of pharmacogenomics in dialysis and transplantationMultigene predictors of tacrolimus exposure in kidney transplant recipients.Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.Parsing interindividual drug variability: an emerging role for systems pharmacology.Characterization of the genetic variation present in CYP3A4 in three South African populations.Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" ProblemProgram in pharmacogenomics at the Ohio State University Medical Center.CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid controlThe CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrationsGenotype-guided tacrolimus dosing in African-American kidney transplant recipients.Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation.The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications.CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy.Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.Cytochrome P450 pharmacogenetics in African populations.Genes and beans: pharmacogenomics of renal transplant.Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs.Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy.The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.Race and ethnicity in cancer therapy: what have we learned?Functional gene variants of CYP3A4.Pharmacogenetics and immunosuppressive drugs in solid organ transplantation.Pharmacogenetics and immunosuppressive drugs.Genetics and nonmelanoma skin cancer in kidney transplant recipients.Use of pharmacogenomics in pediatric renal transplant recipients.Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients.Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation.Targeting myocardial reperfusion injuries with cyclosporine in the CIRCUS Trial - pharmacological reasons for failure.A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation.Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population.
P2860
Q28073025-D2C183BD-B638-4B41-809B-5D25BC7556FAQ28087131-B74AC85A-E189-4324-B48D-61244561E272Q30405394-E5650723-DB14-47C8-8882-351A7E533FD9Q33628473-441AD8CB-45B1-4532-B705-AD2043DB3688Q33989902-3E11F2A2-DD02-4F6B-B562-198D19DEEF47Q34266864-07287209-E22B-4A50-883F-2D2385CB9316Q34307589-6A46A263-E08B-4A2B-93AD-3458F5854E9AQ34454797-F1F59DEC-1662-4FC7-91AD-BAE1167245B4Q35924246-6F563371-2E2F-4160-8ABE-E3F446F7887FQ36410101-506D3AA9-F2CF-484B-882C-3710FC07340AQ36417380-127F92D9-B5F7-42D7-BD90-BB8B3BAABE10Q36617170-F9C0A3A1-E033-409C-B897-83156A10933CQ36634077-9E517838-E5F7-4E4A-952E-FB9B6377507CQ36833654-673E8C7E-4017-4E27-9CC5-49C8033FEF2CQ36927210-7FAA31A1-3C17-4728-9DCA-33D7B7A20147Q36948144-6ACA1501-1E91-4742-90E9-C420741CACE9Q37009025-04924916-01D8-46AD-A057-E076803E987BQ37366663-8A96C948-3ED2-480E-AB92-1FAAB5DD4607Q37513374-CA5B4335-3CB0-4A5A-AD36-0F5A756BEBD8Q37678060-92395DE3-CB51-4373-9BCB-D84D4C0807FDQ38063426-2525E93C-1035-43B6-AA14-1CA26495BAB8Q38068539-A7366783-6965-48A7-B1C4-9389C8339212Q38086777-ED5262EF-B38E-40F6-8FEB-D59D97F913B1Q38099372-0783D794-AF91-4D28-B37F-5B3AF97B57FAQ38104742-53333F2F-A0D3-4CBC-81A9-FBFC32149B61Q38120290-1703D101-A448-4F8F-8785-001AB7EABBBAQ38154911-9C63F5D1-0EDA-40DF-B01B-45FFE04160E1Q38163945-5674FDAA-525C-44CC-8DCE-0CF34AAFEF59Q38178095-DEA18BA7-4604-43DD-9115-5A23C48484A2Q38220008-3B929A0B-2722-47AA-B069-9FA5DE484A86Q38253383-B8448076-5D87-4FD0-8016-FA08FD0BDFAEQ38258677-B4A9AAF1-C22F-4494-953C-03721412A559Q38330222-881591A3-F666-4E98-A563-79C4CFB2ADD4Q38367819-04671769-8252-4C55-85C3-6E3D9C829EC6Q38435024-6737FE53-5580-409C-B0BD-114DD97459A4Q38520159-7F5E0FA4-D3F5-4A94-9DEB-2A4730ACB1D6Q38682136-AB68E95A-5322-4FAE-8E5B-A76A222626C8Q38691788-64FEE369-AEA0-4989-9CC8-A7683EA9CC41Q38787174-752FB07E-4388-40FD-880D-D6CC802D908CQ38937515-90950F55-444C-4A74-9741-79B8E3D71A7F
P2860
Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients
description
scientific article published on 08 September 2011
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2011
@uk
name
Effect of a new functionalCYP3 ...... able renal transplant patients
@en
Effect of a new functionalCYP3 ...... able renal transplant patients
@nl
type
label
Effect of a new functionalCYP3 ...... able renal transplant patients
@en
Effect of a new functionalCYP3 ...... able renal transplant patients
@nl
prefLabel
Effect of a new functionalCYP3 ...... able renal transplant patients
@en
Effect of a new functionalCYP3 ...... able renal transplant patients
@nl
P2093
P2860
P356
P1433
P1476
Effect of a new functional CYP ...... able renal transplant patients
@en
P2093
Martine de Meyer
Michel Mourad
Nadtha Panin
Pierre Wallemacq
Ron H van Schaik
Vincent Haufroid
P2860
P304
P356
10.2217/PGS.11.90
P577
2011-09-08T00:00:00Z